INLYTA

Reason for request

Clinical Benefit

Substantial

The actual benefit of INLYTA in the treatment of renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine is substantial.

Clinical Added Value

minor	The Committee assigns INLYTA a minor improvement in actual benefit (IAB level IV) in terms of efficacy by comparison with NEXAVAR (sorafenib) in the second-line treatment of advanced renal cell carcinoma.
Comments without ASMR value	The Committee cannot quantify the therapeutic benefit of INLYTA in current therapeutic use, i.e. as second-line treatment after the failure of sunitinib.